Research
Improving medicines that patients already depend on
Alongside his Chicago practice, Dr. Palmer leads drug development programs built on metal coordination chemistry.
Published Study
Potential therapy for treatment-resistant
hypothyroidism proves effective in lab study
A new metal-coordinated drug delivery technology potentially could be used to supplement the standard therapy for hypothyroidism, which affects nearly 10 million Americans and many more patients worldwide, according to results of a study published in the journal Thyroid.
Clinical-stage
Steady thyroid hormone, once a day
Thyropeutics is a clinical-stage company developing PZL, an investigational T3 designed to be taken once a day alongside standard thyroid therapy. We’re on a mission to provide a better thyroid medication to the over 20 million Americans who depend on one daily.
Stay Current
Follow Dr. Palmer's research
notes on X
Dr. Palmer shares commentary on metal-coordinated pharmaceuticals, clinical
developments, and Chicago medicine as the work progresses.